MedTrace Logo

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

NCT00222105 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and autologous stem cell transplant.

Conditions

Interventions

DRUG

Doxil

Doxil 40 mg/m2 IV day 1

DRUG

Thalidomide

50-100 mg day 1-28

DRUG

Dexamethasone

Dexamethasone 40 mg day 1-4 and 15-18

Sponsors & Collaborators

  • Ortho Biotech, Inc.

    collaborator INDUSTRY

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Delva Deauna-Limayo, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2009-04-30
Completion
2009-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222105 on ClinicalTrials.gov